Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Divarasib + pembrolizumab vs pembrolizumab + platinum-pemetrexed in first-line KRAS G12C-mutated non-squamous NSCLC
jRCT2071250087Phase 3Recruiting
- Sponsor
- Chugai Pharmaceutical Co., Ltd.
- Start
- Jan 2026
- Modality
- Small Molecules
01
Overview
Phase 3, randomised, open-label trial of divarasib in non-small cell lung cancer (NSCLC) (2 arms), sponsored by Chugai Pharmaceutical Co., Ltd. Primary endpoints: Progression-Free Survival (PFS) and Overall Survival (OS). Started Jan 2026; status: recruiting.
02
Drugs
divarasib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on jRCT2071250087.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2071250087.